Log in

LON:RENXRenalytix Ai Share Price, Forecast & News

GBX 420
-30.00 (-6.67 %)
(As of 05/26/2020 01:35 AM ET)
Add
Compare
Today's Range
420
Now: GBX 420
446.20
50-Day Range
220
MA: GBX 290.92
450
52-Week Range
167.65
Now: GBX 420
370
Volume41,234 shs
Average VolumeN/A
Market Capitalization£249.55 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Renalytix AI plc develops artificial intelligence (AI) enabled clinical decision support solutions for kidney disease. It is developing KidneyIntelX, an AI-enabled, clinical-laboratory based solution that supports physician decision making by improving identification, prediction, and risk stratification of patients with kidney disease. The company is based in Cardiff, the United Kingdom. Renalytix AI plc (AIM:RENX) operates independently of EKF Diagnostics Holdings plc as of November 2, 2018.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£105,000.00
Cash FlowGBX 44.91 per share
Book ValueGBX 70.30 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£249.55 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RENX News and Ratings via Email

Sign-up to receive the latest news and ratings for RENX and its competitors with MarketBeat's FREE daily newsletter.

Renalytix Ai (LON:RENX) Frequently Asked Questions

How has Renalytix Ai's stock been impacted by COVID-19 (Coronavirus)?

Renalytix Ai's stock was trading at GBX 275 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RENX stock has increased by 52.7% and is now trading at GBX 420. View which stocks have been most impacted by Coronavirus.

Has Renalytix Ai been receiving favorable news coverage?

News articles about RENX stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Renalytix Ai earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the near term. View the latest news aboutRenalytix Ai.

Who are some of Renalytix Ai's key competitors?

Who are Renalytix Ai's key executives?

Renalytix Ai's management team includes the following people:
  • Mr. James R. McCullough, CEO & Director (Age 51)
  • Mr. O. James Sterling III, Chief Financial Officer
  • Dr. Sally Bowden, Chief Operating Officer
  • Fergus Fleming, CTO & Director
  • Salim Hamir, Company Sec.

What is Renalytix Ai's stock symbol?

Renalytix Ai trades on the London Stock Exchange (LON) under the ticker symbol "RENX."

How do I buy shares of Renalytix Ai?

Shares of RENX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Renalytix Ai's stock price today?

One share of RENX stock can currently be purchased for approximately GBX 420.

How big of a company is Renalytix Ai?

Renalytix Ai has a market capitalization of £249.55 million and generates £105,000.00 in revenue each year.

What is Renalytix Ai's official website?

The official website for Renalytix Ai is www.renalytixai.com.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.